For years, medical device manufacturers have navigated the Medical Device Regulation (MDR) 2017/745 as if walking through a fog. While the MDR set high safety standards, it left many “procedural gaps” regarding how Notified Bodies (NBs) operate. This led to a frustrating reality: two different manufacturers could experience wildly different costs and timelines for the same type of device.
Potential clients often search for answers to fundamental questions: “How long does MDR certification actually take?” or “Why are Notified Body quotes so inconsistent?” To address these pain points, the European Commission published Implementing Regulation (EU) 2026/977 on May 4, 2026. This act doesn’t replace the MDR but acts as a procedural “cleanup crew” for Annex VII, standardizing how NBs handle applications, fees, and timelines.
What’s changing? Technical Background
Under the original text of Regulation (EU) 2017/745, NBs had significant leeway in interpreting their own internal quality systems. This divergence created an uneven playing field, particularly for Small and Medium-sized Enterprises (SMEs), who often faced unpredictable time-to-market delays. Regulation 2026/977 introduces uniform procedural requirements to ensure that certification becomes a transparent, timed process rather than an open-ended mystery.
Key Questions for Manufacturers
-
Will I finally know my “Time-to-Market” with certainty?
Yes. For the first time, the EU has imposed maximum timelines on Notified Bodies. Once this regulation applies on February 25, 2027, NBs must adhere to strict clocks:
- 30 days to review your application and sign the contract.
- 120 days for the Quality Management System (QMS) audit.
- 90 days for product verification and technical documentation assessment.
- 20 days for the final certification decision after the review is complete.
Practical Impact: You can now build a reliable business plan. However, beware of the “Clock Pause.” If your documentation is incomplete or an NB has technical questions, they can interrupt the timeline. The clock only resumes once you provide the requested information.
-
Can I compare costs between different Notified Bodies?
The new regulation mandates standardized quotations. NBs can no longer issue vague estimates. They must request specific information upfront—such as your SME status, the number of work shifts at your sites, and a detailed description of the device’s technology—to issue a binding quote. These quotes must now include a clear breakdown of estimated overall costs, including typical fees for surveillance activities and unannounced audits. Furthermore, NBs must inform you in advance if costs are expected to increase by more than 10%. -
Is re-certification still a “start from scratch” process?
Fortunately, no. The new rules clarify that re-certification should not repeat the initial assessment. Instead, it will focus on what has changed since the last audit: updates to the state of the art, post-market surveillance (PMS) data, and changes to the device or its risk-benefit ratio. This streamlines the process for established products, keeping them on the market with less administrative friction.
The Future of Transparency
To ensure these rules aren’t just “ink on paper,” NBs are now required to monitor their own performance. Every year, they must publish a report on their website showing the median duration and costs of their certification activities. This allows manufacturers to compare NBs based on actual data rather than marketing promises.
How Chemsafe Can Help
While Regulation 2026/977 forces Notified Bodies to be faster, it does not lower the bar for quality. In fact, because the “clock” can be paused for non-compliances, the pressure is now on the manufacturer to submit a flawless technical file from day one.
At Chemsafe, our team of senior toxicologists, ERTs, and regulatory experts specializes in turning the MDR’s complexity into a structured, efficient path. We provide:
- Regulatory Gap Analysis (MDD to MDR): To identify and fix documentation deficiencies before you apply to an NB.
- Technical Documentation Preparation: Ensuring your file is “ready to audit” to avoid timeline interruptions.
- Expert Reports for Substance-Based Devices: Handling complex biological and toxicological evaluations (ISO 10993) that often cause NB delays.
- PRRC and Authorized Representative Services: Managing the ongoing compliance required to maintain your certificate under the new surveillance rules.
Don’t let an incomplete file stop the clock on your innovation. Contact Chemsafe today to ensure your certification process is as predictable as the new regulation intended
